Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Male Breast Cancer|Recurrent Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer
Interventions: DRUG: anastrozole|DRUG: pazopanib hydrochloride|PROCEDURE: therapeutic conventional surgery
Sponsor: University of Arizona
Collaborators: National Cancer Institute (NCI)|GlaxoSmithKline